All In Biotech

Drug Trial Radar · NCT02587065

Plegridy Satisfaction Study in Participants

Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Plegridy (Pre-filled Pen) in Subjects With Relapsing-remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM)

Last checked: Nov 20, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

193

Actual

Start

Feb 3, 2016

Primary completion

Oct 2, 2017

Study completion Dec 21, 2017

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Oct 27, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to investigate whether Peg-IFN beta-1a improves the satisfaction of Relapsing-Remitting Multiple Sclerosis (RRMS) participants unsatisfied with injectable subcutaneous Interferons, as measured by the Abbreviated Treatment Satisfaction Questionnaire to Medication (TSQM-9), at 12 weeks. The secondary objectives of this study are to evaluate in this study population: effects of Peg-IFN beta-1a treatment on participants' satisfaction at 24 weeks; effects of Peg-IFN beta-1a treatment on short-term participants' adherence; effects of Peg-IFN beta-1a treatment on participants' fatigue; effects of Peg-IFN beta-1a on disease activity and physical disability; impact of Peg-IFN beta-1a treatment on participant-reported health-related quality of life; impact of Peg-IFN beta-1a treatment on participants' injection-system satisfaction; Evaluate the relationship between participants' satisfaction and adherence; Evaluate the relationship between participants' satisfaction and social-demographic factors (age, sex, employment working, level of education, etc) and clinical characteristics (annualized relapse rate \[ARR\], disability, etc.) and to evaluate the treatment safety and tolerability.

Conditions

  • Relapsing-Remitting Multiple Sclerosis (RRMS)

Interventions

  • peginterferon beta-1aDrug

    125 mcg administered subcutaneously (SC) every 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Convenience Satisfaction Score of Treatment Satisfaction Questionnaire to Medication (TSQM-9) at Week 12Time frame: Baseline, Week 12

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Arezzo, Italy

  • Research Site

    Bari, Italy

  • Research Site

    Cagliari, Italy

  • Research Site

    Cefalù, Italy

  • Research Site

    Chieti, Italy

  • Research Site

    Como, Italy

  • Research Site

    Fidenza, Italy

  • Research Site

    Foligno, Italy

  • Research Site

    Gallarate, Italy

  • Research Site

    Genova, Italy

  • Research Site

    L’Aquila, Italy

  • Research Site

    Messina, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Modena, Italy

  • Research Site

    Mondovì, Italy

  • research Site

    Naples, Italy

  • Research Site

    Naples, Italy

  • Research Site

    Orbassano, Italy

  • Research Site

    Ozieri, Italy

  • Research Site

    Palermo, Italy

  • Research Site

    Palermo, Italy

  • Research Site

    Pavia, Italy

  • Research Site

    Pietra Ligure, Italy

  • Research Site

    Pozzilli, Italy

  • Research Site

    Reggio Calabria, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Torino, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.